Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

One-Third Of Supplement GMP Inspections Reveal "Serious Problems" - FDA

This article was originally published in The Tan Sheet

Executive Summary

About one-third of the 90 dietary supplement good manufacturing practices inspections FDA completed in fiscal 2010 by the start of September revealed serious compliance problems, according to Principal Deputy Commissioner Josh Sharfstein

You may also be interested in...



Dietary Supplement GMP Warning Letters

Dietary supplement manufacturers’ responses to FDA reports of good manufacturing practices problems not only are inadequate, but in some instances prompt the agency to warn of checking for corrective actions in later inspections, according to recently posted warning letters.

Dietary Supplement GMP Warning Letters

Dietary supplement manufacturers’ responses to FDA reports of good manufacturing practices problems not only are inadequate, but in some instances prompt the agency to warn of checking for corrective actions in later inspections, according to recently posted warning letters.

FDA War On Tainted Supplements Wages On

A warning letter about tainted dietary supplements is a reminder that even though recalls of spiked supplements are declining, products marketed as supplements that contain undeclared prescription drugs still infiltrate the market. The letter illustrates recalling tainted supplements may not prevent future enforcement actions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel